Cardiovascular Stock Analysis

CSII -  USA Stock  

USD 18.07  0.08  0.44%

The big decline in price over the last few months for Cardiovascular Syst could raise concerns from stockholders as the firm it trading at a share price of 18.07 on very low momentum in volume. The company executives failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Cardiovascular Syst or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.82. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Cardiovascular Syst partners.
Continue to Trending Equities.

Cardiovascular Stock Analysis 

 
Refresh
The Cardiovascular Syst stock analysis report makes it easy to digest most publicly released information about Cardiovascular Syst and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Cardiovascular Stock analysis module also helps to analyze the Cardiovascular Syst price relationship with some important fundamental indicators such as market cap and management efficiency.

Cardiovascular Stock Analysis Notes

About 95.0% of the company shares are held by institutions such as insurance companies. The book value of Cardiovascular Syst was currently reported as 6.49. The company has Price/Earnings To Growth (PEG) ratio of 1.46. Cardiovascular Syst recorded a loss per share of 0.52. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 26th of February 2009. Cardiovascular Systems, Inc., a medical device company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota. Cardiovascular Syst operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 780 people. For more info on Cardiovascular Syst please contact Scott Ward at 651 259-1600 or go to www.csi360.com.

Cardiovascular Syst Quarterly Cost of Revenue

14.31 MillionShare

Cardiovascular Syst Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Cardiovascular Syst's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Cardiovascular Syst or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Cardiovascular Syst generated a negative expected return over the last 90 days
Cardiovascular Syst has high historical volatility and very poor performance
Cardiovascular Syst is unlikely to experience financial distress in the next 2 years
Cardiovascular Syst was previously known as Cardiovascular Systems and was traded on NASDAQ Exchange under the symbol RDYN.
The company reported the previous year's revenue of 256.8 M. Net Loss for the year was (19.96 M) with profit before overhead, payroll, taxes, and interest of 197.84 M.
Cardiovascular Syst currently holds about 187.62 M in cash with (9.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.63.
Over 95.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.nature.com: Identification of a regulatory pathway inhibiting adipogenesis via RSPO2 - Nature.com

Cardiovascular Syst Upcoming and Recent Events

Earnings reports are used by Cardiovascular Syst to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cardiovascular Syst previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report3rd of February 2022
Next Earnings Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End3rd of August 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Cardiovascular Largest EPS Surprises

Earnings surprises can significantly impact Cardiovascular Syst's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2017-05-03
2017-03-31-0.045-0.05-0.00511 
2020-05-05
2020-03-31-0.1-0.080.0220 
2017-10-25
2017-09-30-0.085-0.060.02529 
View All Earnings Estimates

Cardiovascular Syst SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Cardiovascular Syst prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Cardiovascular Syst investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Cardiovascular Syst specific information freely available to individual and institutional investors to make a timely investment decision.
24th of November 2021
Financial Statements and Exhibits. Other Events
View
12th of November 2021
Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
9th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
22nd of September 2021
Regulation FD Disclosure
View
20th of August 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
4th of August 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
23rd of July 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
6th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

Cardiovascular Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Cardiovascular Syst is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cardiovascular Syst backward and forwards among themselves. Cardiovascular Syst's institutional investor refers to the entity that pools money to purchase Cardiovascular Syst's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Exchange Traded Concepts LlcCommon Shares176.5 K3.3 M
State Of Alaska Department Of RevenueCommon Shares28.7 K539 K
Louisiana State Employees Retirement SystemCommon Shares19.6 K368 K
Diversified Trust CoCommon Shares17.9 K335 K
Versant Capital Management IncCommon Shares98819 K
Blackrock IncCommon Shares6.7 M219.9 M
Brown Capital Management LlcCommon Shares5.9 M194.9 M
Note, although Cardiovascular Syst's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cardiovascular Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 732.75 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cardiovascular Syst's market, we take the total number of its shares issued and multiply it by Cardiovascular Syst's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Cardiovascular Profitablity

Cardiovascular Syst's profitability indicators refer to fundamental financial ratios that showcase Cardiovascular Syst's ability to generate income relative to its revenue or operating costs. If, let's say, Cardiovascular Syst is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Cardiovascular Syst's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Cardiovascular Syst's profitability requires more research than a typical breakdown of Cardiovascular Syst's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (7.77) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (7.16) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.07.
Last ReportedProjected for 2022
Return on Investment(3.70) (3.99) 
Return on Average Assets(0.0448) (0.0484) 
Return on Average Equity(0.06) (0.06) 
Return on Invested Capital(0.06) (0.06) 
Return on Sales(0.05) (0.05) 

Management Efficiency

The entity has return on total asset (ROA) of (3.41) % which means that it has lost $3.41 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (7.51) %, meaning that it created substantial loss on money invested by shareholders. Cardiovascular Syst management efficiency ratios could be used to measure how well cardiovascular syst manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -3.99. The current Return on Average Assets is estimated to decrease to -0.05. Cardiovascular Syst Goodwill and Intangible Assets are most likely to increase significantly in the upcoming years. The last year's value of Goodwill and Intangible Assets was reported at 17.68 Million. The current Revenue to Assets is estimated to increase to 1.08, while Current Assets are projected to decrease to roughly 260.2 M.
Last ReportedProjected for 2022
Book Value per Share 8.02  6.65 
Enterprise Value over EBIT(166.75) (171.14) 
Enterprise Value over EBITDA(267.76) (274.81) 
Price to Book Value 5.69  6.05 
Tangible Assets Book Value per Share 9.99  8.55 
Enterprise Value1.9 B2.1 B
Tangible Asset Value387.8 M306.3 M

Technical Drivers

As of the 23rd of January, Cardiovascular Syst shows the risk adjusted performance of (0.18), and Mean Deviation of 2.8. Cardiovascular Syst technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Cardiovascular Syst, which can be compared to its rivals. Please confirm Cardiovascular Syst treynor ratio, as well as the relationship between the downside variance and kurtosis to decide if Cardiovascular Syst is priced correctly, providing market reflects its regular price of 18.07 per share. Given that Cardiovascular Syst has jensen alpha of (0.77), we suggest you to validate Cardiovascular Syst's prevailing market performance to make sure the company can sustain itself at a future point.

Cardiovascular Syst Price Movement Analysis

The output start index for this execution was thirty-nine with a total number of output elements of twenty-two. View also all equity analysis or get more info about mavp overlap studies indicator.

Cardiovascular Syst Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cardiovascular Syst insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cardiovascular Syst's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cardiovascular Syst insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Augustine Lawlor over two months ago via Macroaxis 
Cardiovascular Syst exotic insider transaction detected
Whitescarver David over two months ago via Macroaxis 
Payment of 429 shares by Whitescarver David of Cardiovascular Syst subject to Rule 16b-3
Jeffrey Points over three months ago via Macroaxis 
Payment of 778 shares by Jeffrey Points of Cardiovascular Syst subject to Rule 16b-3
Whitescarver David over three months ago via Macroaxis 
Payment of 1009 shares by Whitescarver David of Cardiovascular Syst subject to Rule 16b-3
Rempe Stephen J over three months ago via Macroaxis 
Payment of 1526 shares by Rempe Stephen J of Cardiovascular Syst subject to Rule 16b-3
Jain Sachin H over three months ago via Macroaxis 
Acquisition by Jain Sachin H of 3814 shares of Cardiovascular Syst subject to Rule 16b-3
Rempe Stephen J over six months ago via Macroaxis 
Payment of 226 shares by Rempe Stephen J of Cardiovascular Syst subject to Rule 16b-3
Jeffrey Points over six months ago via Macroaxis 
Purchase by Jeffrey Points of 1000 shares of Cardiovascular Syst
Edward Brown over six months ago via Macroaxis 
Cardiovascular Syst exotic insider transaction detected
Rhonda Robb over six months ago via Macroaxis 
Payment of 19152 shares by Rhonda Robb of Cardiovascular Syst subject to Rule 16b-3
Jain Sachin H over six months ago via Macroaxis 
Acquisition by Jain Sachin H of 1333 shares of Cardiovascular Syst subject to Rule 16b-3
Whitescarver David over a year ago via Macroaxis 
Payment of 429 shares by Whitescarver David of Cardiovascular Systems subject to Rule 16b-3

Cardiovascular Syst Technical and Predictive Indicators

Cardiovascular Syst Forecast Models

Cardiovascular Syst time-series forecasting models is one of many Cardiovascular Syst's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cardiovascular Syst's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Cardiovascular Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cardiovascular Syst stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cardiovascular shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Cardiovascular Syst. By using and applying Cardiovascular Stock analysis, traders can create a robust methodology for identifying Cardiovascular entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin(4.15) (4.47) 
EBITDA Margin(0.0322) (0.0347) 
Gross Margin 0.88  0.92 
Profit Margin(0.06) (0.06) 
Cardiovascular Systems, Inc., a medical device company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota. Cardiovascular Syst operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 780 people.

Current Cardiovascular Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cardiovascular analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cardiovascular analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
41.43Hold7Odds
Cardiovascular Syst current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Cardiovascular analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Cardiovascular stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Cardiovascular Syst, talking to its executives and customers, or listening to Cardiovascular conference calls.
Cardiovascular Analyst Advice Details

Cardiovascular Stock Analysis Indicators

Cardiovascular Syst stock analysis indicators help investors evaluate how Cardiovascular Syst stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cardiovascular Syst shares will generate the highest return on investment. By understating and applying Cardiovascular Syst stock analysis, traders can identify Cardiovascular Syst position entry and exit signals to maximize returns.
Quick Ratio5.21
Fifty Two Week Low17.51
Revenue Growth-3.60%
Shares Short Prior Month967.51k
Average Daily Volume Last 10 Day506.59k
Average Daily Volume In Three Month444.77k
Shares Percent Shares Out2.15%
Gross Margins75.52%
Short Percent Of Float3.32%
Forward Price Earnings-129.07
Float Shares37.04M
Fifty Two Week High48.28
Enterprise Value To Ebitda-42.90
Fifty Day Average20.76
Two Hundred Day Average33.27
Enterprise Value To Revenue2.31
Continue to Trending Equities. Note that the Cardiovascular Syst information on this page should be used as a complementary analysis to other Cardiovascular Syst's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for Cardiovascular Stock analysis

When running Cardiovascular Syst price analysis, check to measure Cardiovascular Syst's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiovascular Syst is operating at the current time. Most of Cardiovascular Syst's value examination focuses on studying past and present price action to predict the probability of Cardiovascular Syst's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cardiovascular Syst's price. Additionally, you may evaluate how the addition of Cardiovascular Syst to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Is Cardiovascular Syst's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiovascular Syst. If investors know Cardiovascular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiovascular Syst listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cardiovascular Syst is measured differently than its book value, which is the value of Cardiovascular that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiovascular Syst's value that differs from its market value or its book value, called intrinsic value, which is Cardiovascular Syst's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiovascular Syst's market value can be influenced by many factors that don't directly affect Cardiovascular Syst's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiovascular Syst's value and its price as these two are different measures arrived at by different means. Investors typically determine Cardiovascular Syst value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiovascular Syst's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.